Show simple item record

dc.contributor.authorSchu, Sabine
dc.contributor.authorNosov, Mikhail
dc.contributor.authorO'Flynn, Lisa
dc.contributor.authorShaw, Georgina
dc.contributor.authorTreacy, Oliver
dc.contributor.authorBarry, Frank
dc.contributor.authorMurphy, Mary
dc.contributor.authorO'Brien, Timothy
dc.contributor.authorRitter, Thomas
dc.date.accessioned2018-09-20T16:24:10Z
dc.date.available2018-09-20T16:24:10Z
dc.date.issued2012-08-23
dc.identifier.citationSchu, Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine 16 (9), 2094-2103
dc.identifier.issn1582-1838
dc.identifier.urihttp://hdl.handle.net/10379/13837
dc.description.abstractMesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic rat MSCs against cytotoxic lysis in vitro and result in a reduced immune response in vivo. Rat MSCs were partially protected against alloantigen-specific cytotoxic T cells in vitro. However, after treatment with IFN-? and IL-1 beta, MSCs upregulated MHCI, MHCII and VCAM-1, and cytotoxic lysis was significantly increased. In vivo, allogeneic T cells but not allogeneic MSCs induced upregulation of the activation markers CD25 and CD71 as well as downregulation of CD62L on CD4+ T cells from recipient rats. However, intravenous injection of allo-MSCs in rats led to the formation of alloantibodies with the capacity to facilitate complement-mediated lysis, although IgM levels were markedly decreased compared with animals that received T cells. The allo-MSC induced immune response was sufficient to lead to significantly reduced survival of subsequently injected allo-MSCs. Interestingly, no increased immunogenicity of IFN-? stimulated allo-MSCs was observed in vivo. Both the loss of protection against cytotoxic lysis under inflammatory conditions and the induction of complement-activating antibodies will likely impact the utility of allogeneic MSCs for therapeutic applications.
dc.publisherWiley-Blackwell
dc.relation.ispartofJournal of Cellular and Molecular Medicine
dc.subjectmesenchymal stem cells
dc.subjectallo-antibody
dc.subjectcomplement
dc.subjectimmunogenicity
dc.subjectacute myocardial-infarction
dc.subjectproliferation in-vitro
dc.subjectmarrow stromal cells
dc.subjectversus-host-disease
dc.subjectacute-renal-failure
dc.subjectimmune-response
dc.subjectcardiac allograft
dc.subjectgene-therapy
dc.subjectnitric-oxide
dc.subjectcalf serum
dc.titleImmunogenicity of allogeneic mesenchymal stem cells
dc.typeArticle
dc.identifier.doi10.1111/j.1582-4934.2011.01509.x
dc.local.publishedsourcehttp://onlinelibrary.wiley.com/doi/10.1111/j.1582-4934.2011.01509.x/pdf
nui.item.downloads0


Files in this item

This item appears in the following Collection(s)

Show simple item record